相关实验视频
Updated: Jun 26, 2025
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
49.9K
纳利鲁丁通过调节肠道菌群,缓解了小鼠的酸糖硫酸引起的结肠炎
Dianwen Xu1, Dianfeng Liu2, Naiyuan Jiang3
1State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun 130062, China.
概括
纳里鲁丁 (NR) 通过调节肠道微生物群,有效治疗小鼠的性结肠炎 (UC). 这种天然化合物保护肠道屏障并减少炎症,为UC管理提供了有前途的治疗途径.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性胃肠道炎症疾病,治疗选择有限.
- 类黄类的纳里鲁丁 (NR) 在体外显示出抗炎性质,但在体内缺乏UC研究.
- 探索UC的新型治疗策略至关重要.
研究的目的:
- 在小鼠模型中研究纳里鲁丁 (NR) 对硫酸 (DSS) 诱导的性结肠炎 (UC) 的治疗作用.
- 阐明肠道微生物群在NR对大肠炎的保护作用中的作用.
主要方法:
- 在接受不同剂量的NR (10,20,40 mg/kg) 治疗的小鼠中,DSS诱导的UC模型.
- 评估临床参数 (体重,DAI,结肠长度,组织学) 和分子标记物 (促炎媒介,紧结蛋白,信号通路).
- 分析肠道微生物群组成 (16S rRNA测序),植物清除和便微生物群移植 (FMT),以确定肠道菌群的作用.
主要成果:
- 服用NR显著改善了DSS诱导的大肠炎,减少了体重减轻,疾病活动,结肠缩短和组织学损伤.
- 通过保持紧密结合蛋白,NR保持了肠道屏障的完整性,并抑制了TLR4-MAPK/NF-κB炎症途径.
- NR治疗丰富了肠道微生物的多样性,增加了有益的乳酸菌,减少了有害的细菌和菌,清除和FMT测试显示,其影响取决于肠道菌群.
结论:
- 纳里鲁丁 (NR) 在治疗性结肠炎 (UC) 中显示出显著的治疗潜力.
- 通过调节肠道菌群,NR对结肠炎的保护作用是介导的.
- 通过肠道微生物群调节,NR代表了通过肠道微生物群调节来管理UC的有希望的天然化合物.
更多相关视频
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
136
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
136
01:17Drugs for Treatment of Diarrhea-Predominant IBS
161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161